Ad
related to: sangamo therapeutics
Search results
We Think Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package Needs To Be Put Under A...
Simply Wall St. via Yahoo Finance· 2 days agoKey Insights Sangamo Therapeutics will host its Annual General Meeting on 4th of June Salary of...
In the wake of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) latest US$56m market cap drop,...
Simply Wall St. via Yahoo Finance· 1 year agoKey Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have...
Recent uptick might appease Sangamo Therapeutics, Inc. (NASDAQ:SGMO) institutional owners after...
Simply Wall St. via Yahoo Finance· 9 months agoKey Insights Significantly high institutional ownership implies Sangamo Therapeutics' stock price is...
With 55% ownership of the shares, Sangamo Therapeutics, Inc. (NASDAQ:SGMO) is heavily dominated by...
Simply Wall St. via Yahoo Finance· 4 months agoKey Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have...
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Shares Lagging The Industry But So Is The Business
Simply Wall St. via Yahoo Finance· 1 year agoYou may think that with a price-to-sales (or "P/S") ratio of 2.5x Sangamo Therapeutics, Inc....
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 weeks agoSangamo Therapeutics, Inc. (NASDAQ:SGMO) Q1 2024 Earnings Call Transcript May 9, 2024 Sangamo...
Is Sangamo Therapeutics (NASDAQ:SGMO) In A Good Position To Deliver On Growth Plans?
Simply Wall St. via Yahoo Finance· 2 years agoEven when a business is losing money, it's possible for shareholders to make money if they buy a...
Does This Valuation Of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Imply Investors Are Overpaying?
Simply Wall St. via Yahoo Finance· 10 months agoKey Insights The projected fair value for Sangamo Therapeutics is US$0.84 based on 2 Stage Free Cash...
Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Could Be Quite Risky
Simply Wall St. via Yahoo Finance· 6 months agoWe can readily understand why investors are attracted to unprofitable companies. For example,...
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) recent 7.9% pullback adds to one-year year losses,...
Simply Wall St. via Yahoo Finance· 2 years agoTo get a sense of who is truly in control of Sangamo Therapeutics, Inc. (NASDAQ:SGMO), it is...
